NCT05646576 Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
| NCT ID | NCT05646576 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Hematologic Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2022-12-30 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2022-12-30 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Ability to complete surveys in English or with assistance of an interpreter. * Diagnosis of a hematologic malignancy. * Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product. Exclusion Criteria: * Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment. * Already receiving palliative care (PC).
Contact & Investigator
Patrick C Johnson, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05646576 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05646576 currently recruiting?
Yes, NCT05646576 is actively recruiting participants. Contact the research team at PCJOHNSON@MGH.HARVARD.EDU for enrollment information.
Where is the NCT05646576 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05646576 clinical trial?
NCT05646576 is sponsored by Massachusetts General Hospital. The principal investigator is Patrick C Johnson, MD at Massachusetts General Hospital. The trial plans to enroll 90 participants.